Xymax Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 107.02%
- Profit Growth 6.43%
- Ebitda 152.52%
- Net Worth 14.17%
- Total Assets 41.64%
About Xymax Laboratories
Xymax Laboratories Private Limited (XLPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 May 2017 (Seven years and nine months 8 days old ). Its registered office is in Karnal, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Deepak Arora and Bhawna Arora serve as directors at the Company.
Company Details
- Location
Karnal, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909HR2017PTC069047
- Company No.
069047
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 May 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Xymax Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Arora  | Director | 17-May-2017 | Current |
| Bhawna Arora | Director | 17-May-2017 | Current |
Financial Performance of Xymax Laboratories.
Xymax Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 107.02% increase. The company also saw a slight improvement in profitability, with a 6.43% increase in profit. The company's net worth Soared by an impressive increase of 14.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xymax Laboratories?
Unlock access to Xymax Laboratories's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Xymax Health Care Private LimitedDeepak Arora is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xymax Laboratories?
Unlock and access historical data on people associated with Xymax Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xymax Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xymax Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.